Published on in Vol 6, No 12 (2017): December

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/8057, first published .
Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial

Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial

Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial

Journals

  1. Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics 2019;41(10):2137 View
  2. Barsky L, Merz C, Wei J, Shufelt C, Handberg E, Pepine C, Rutledge T, Reis S, Doyle M, Rogers W, Shaw L, Sopko G. Even “WISE-R?”—an Update on the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation. Current Atherosclerosis Reports 2020;22(8) View
  3. Kofler T, Hess S, Moccetti F, Pepine C, Attinger A, Wolfrum M, Toggweiler S, Kobza R, Cuculi F, Bossard M. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials. CJC Open 2021;3(1):101 View
  4. Massoomi M, Handberg E. Increasing and Evolving Role of Smart Devices in Modern Medicine. European Cardiology Review 2019;14(3):181 View
  5. Sharp R, Patatanian E, Sirajuddin R. Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction. American Journal of Cardiovascular Drugs 2021 View